

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of
Inventor(s): Hans-Michael Jantzen and Pamela B. Conley,

For: NOVEL PURINERGIC RECEPTOR

1. Type of Application

This new application is for a(n)

- ☐ Original (nonprovisional)
- ☐ Design
- ☐ Plant
- ☒ Divisional.
- ☐ Continuation.
- ☐ Continuation-in-part (C-I-P).

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV312194681US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker/Carolyn Willey

(type or print name of person certifying)

Date: November 12, 2003

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).
"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. : MPI95-017P1RCN3DV1M

2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)

- ☒ The new application being transmitted claims the benefit of prior U.S. Application Number 09/947,922 filed September 7, 2001.

3. Maintenance of Copendency of Prior Application

- A. ☐ Extension of time in prior application
- B. ☐ Conditional Petition for Extension of Time in Prior Application

(complete this item, if previous item not applicable)

- ☐ A conditional petition for extension of time is being filed in the pending **prior** application.
- ☐ A **copy** of the conditional petition filed in the prior application is attached.

4. Abandonment of Prior Application (if applicable)

- ☐ Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

Notification in Parent Application of This Filing

- ☐ A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

5. Papers Enclosed

Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application

28 Pages of Specification, including
25 Pages of Description
2 Pages of Claims
1 Page of Abstract
5 Sheets of Drawings (Figure(s) 1A, 1B, 1C, 2 and 3)

- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).
- ☒ Formal
- ☐ Informal

Practitioner's Docket No. : MPI95-017P1RCN3DV1M

6. Additional Papers Enclosed

- ☒ A copy of an Information Disclosure Statement (37 C.F.R. Section 1.98) as filed in U.S. Application No. 09/947,922 filed September 7, 2001
- ☒ A copy of Form PTO-1449 (PTO/SB/08A and 08B) as filed in U.S. Application No. 09/947,922 filed September 7, 2001
- ☐ Citations
- ☐ Declaration of Biological Deposit
- ☒ 11 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823), and 4 pages of Submission of "Sequence Listing,"
- ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- ☐ Special Comments
- ☒ Other: Information Disclosure Statement Transmittal requesting copies of references as filed in U.S. Application No. 09/947,922 filed September 7, 2001 be transferred.

7. Declaration or Oath (including power of attorney)

- ☒ (3 pages) An executed Combined Declaration and Power of Attorney as filed in U.S. Application Serial No. 09/947,922 filed on September 7, 2001, copy of which is enclosed.
- ☐ Not Enclosed.

8. Assignment

- ☒ An assignment of the invention to COR Therapeutics, Inc. as filed in U.S. Application Serial No. 08/749,707 (Patent No. 6,063,582) filed on March 12, 1997 the earliest priority application (a copy of which is enclosed) and a copy of Certificate of Ownership and Merger merging COR Therapeutics, Inc. into Millennium Pharmaceuticals, Inc., as filed in U.S. Application Serial No. 09/947,922 filed on September 7, 2001 a copy of which
 - ☒ is enclosed.
 - ☐ will follow.

9. Related Applications

Amend the specification by inserting after the Title, the following:

This application is a divisional of U.S. Application Serial No. 09/947,922, filed September 7, 2001, which is a continuation of U.S. Application Serial No. 09/410,738, filed October 1, 1999 (abandoned), which is a continuation of U.S. Application No. 08/749,707, filed November 15, 1996 (Patent No. 6,063,582), which is a continuation of U.S. Application No. 08/559,524, filed November 15, 1995 (Patent No. 5,871,963), and which claims the benefit of U.S. Application Serial No. 60/006,782, filed November 15, 1995.

Practitioner's Docket No. : **MPI95-017P1RCN3DV1M**

10. Fee Calculation (37 C.F.R. Section 1.16)

A. ☒ Regular application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$770.00
Total Claims (37 C.F.R. Section 1.16(c))	15	- 20 =	0	\$18.00	\$0.00
Independent Claims (37 C.F.R. Section 1.16(b))	1	- 3 =	0	\$86.00	\$0.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	\$290.00			\$0.00

Filing Fee Calculation

\$770.00

- ☐ Amendment canceling extra claims is enclosed.
☐ Amendment deleting multiple-dependencies is enclosed.
☐ Fee for extra claims is not being paid at this time.

Practitioner's Docket No. : MPI95-017P1RCN3DV1M

11. Method of Payment of Fees

- ☐ Check in the amount of \$_____.
- ☒ Charge Account No. 501668 in the amount of \$770.00
A duplicate of this transmittal is attached.

12. Authorization to Charge Additional Fees

- ☒ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.
- ☒ 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)
- ☒ 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)
- ☐ 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
- ☐ 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a).
- ☐ 37 C.F.R. Section 1.17 (application processing fees)
- ☐ 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

13. Instructions as to Overpayment

- ☒ Credit Account No. 501668.
- ☐ Refund

Practitioner's Docket No. : **MPI95-017P1RCN3DV1M**

14. Correspondence Address

Direct all future correspondence to:

Customer Number 30405


OR

Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139

November 12, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By


Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820

☒ **Statement Where No Further Pages Added**

☒ This transmittal ends with this page.